Thomas D. Ingolia

Medisyn Technologies, Inc. develops novel pharmaceuticals, nutraceuticals, and animal health products. The firm engages in the development of pre-qualified proprietary drug compounds. Its Forward Engineering platform is focused on predicting the behavior of molecules from topology. The company was founded in 1999 and is headquartered in Minnetonka, MN.

Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation.